Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8433374 | 0.86 | CYP1A2 (0.38) | MEN1KMT2ANPC1RAB9ACYP1A2 | |
| SCHEMBL4549150 | 0.85 | GRM5 (0.32) | — | |
| SCHEMBL2959900 | 0.85 | MTOR (0.32) | — | |
| SCHEMBL7562202 | 0.85 | ALDH1A1 (0.36) | MEN1KMT2A | |
| SCHEMBL2959902 | 0.85 | MTOR (0.32) | — | |
| SCHEMBL7556413 | 0.85 | MTOR (0.37) | MEN1KMT2ANPC1RAB9ACYP1A2 | |
| SCHEMBL2959783 | 0.83 | MGLL (0.34) | EPHX2 | |
| SCHEMBL4549146 | 0.83 | LMNA (0.33) | — | |
| SCHEMBL7574379 | 0.83 | BACE1 (0.41) | NOTUM | |
| SCHEMBL2959787 | 0.83 | MGLL (0.34) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | EPHX2 2885/4885AR 3618/4885MEN1 730/4885 |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | EPHX2 2885/4885AR 3618/4885MEN1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.